Skip to main content
. 2018 Jan 24;9(2):92. doi: 10.1038/s41419-017-0134-0

Fig. 2. miR-375 directly targets YAP1, TEAD4, and CTGF in GC.

Fig. 2

a The putative miR-375 binding sites in the 3’UTR of YAP1, TEAD4, and CTGF as predicted by www.microrna.org and www.targetscan.org. b mRNA expression of YAP1, TEAD4, and CTGF after miR-375 transfection in AGS, NCI-N87, and MGC-803 cells (**, P< 0.001). c miR-375 ectopic expression decreased YAP1, TEAD4, and CTGF protein expression in AGS, NCI-N87, and MGC-803 cells. d miR-375 suppressed the relative luciferase activity in the constructs which contain the wild type sequence of the binding site in the 3’UTR of YAP1 (only binding site 2), TEAD4, and CTGF (*, P< 0.05; **, P< 0.001). Wild type, luciferase construct containing wild type binding site in YAP1 3’UTR; Mutation, mutated nucleotides were introduced to the complementary seed sequence. e YAP1 and CTGF protein expression showed negative correlation with miR-375 expression in primary gastric tumors (n = 28, P< 0.001 and P= 0.044, respectively)